Richard A. Pigg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Richard A. Pigg has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Gunn
University of Kentucky College of Medicine, Lexington, USA
2 shared publications - Cody H. Savage
Division of Vascular and Interventional Radiology, Department of Radiology, University of Alabama at Birmingham, Birmingham, USA
2 shared publications - Junjian Huang
University of Alabama at Birmingham
2 shared publications - Yufeng Li
Section of Interventional Radiology, Department of Radiology, UAB Heersink School of Medicine, JTN 444, 619 19th St S, Birmingham, AL 35294, United States of America
2 shared publications - Aron Michael Devane
University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA
1 shared publication - Christine Marie Gilligan Schammel
University of South Carolina School of Medicine-Greenville, Greenville, USA
1 shared publication
Latest Publications
- 27 December 2023
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (3) , 919-926
Percutaneous cryoablation of 100 anterior renal tumors: safety and technical success
Purpose To assess the safety, technical success, and clinical outcomes of percutaneous cryoablation (PCA) in patients with anterior renal tumors. Methods A retrospective analysis of patients with anterior renal tumors, defined as tumors at or anterior to the level of the renal pelvis, treated with CT-guided PCA from 2008 to 2022. Summary statistics included demographics and baseline tumor attributes. Treatment and follow-up metrics included primary and secondary technical success, adverse events (AEs) according to the SIR classification, local recurrence, overall survival (OS), and cancer-specific survival (CSS)). 100 patients (60 males; mean age: 63, mean BMI: 33, mean Charlson comorbidity index:6) with 100 anterior renal tumors were included. Results 78% of tumors were T1a and 22% T1b with mean maximal tumoral dimension of 29 mm (range: 6–62 mm) and mean distance to nearest critical structure 9 mm (range: 0–40 mm). Mean follow-up was 20.9 months (range: 3–103). 28% of PCAs required hydrodissection. Technical success was achieved in 92% of patients; with six remaining patients undergoing successful repeat PCA (secondary technical success: 98%). The remaining two patients without primary technical success were either surveilled or had a benign pathology on resulted concomitant biopsy. Four patients (4%) had major AEs (hemorrhage requiring prolonged admission, transfusion, or embolization (n = 3), perinephric abscess requiring drainage (n = 1)) and 27% had minor AEs. Eight patients (8%) had recurrence with a one-year OS of 94% and CSS of 100%. All recurrences underwent repeat ablation without additional recurrence and 3/8 (38%) were T1b and 5/8 (63%) were T1a tumors. Conclusion PCA of anterior renal tumors can be performed safely with high rates of technical and oncologic success.
- 27 December 2023
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (3) , 919-926
Percutaneous cryoablation of 100 anterior renal tumors: safety and technical success
Purpose To assess the safety, technical success, and clinical outcomes of percutaneous cryoablation (PCA) in patients with anterior renal tumors. Methods A retrospective analysis of patients with anterior renal tumors, defined as tumors at or anterior to the level of the renal pelvis, treated with CT-guided PCA from 2008 to 2022. Summary statistics included demographics and baseline tumor attributes. Treatment and follow-up metrics included primary and secondary technical success, adverse events (AEs) according to the SIR classification, local recurrence, overall survival (OS), and cancer-specific survival (CSS)). 100 patients (60 males; mean age: 63, mean BMI: 33, mean Charlson comorbidity index:6) with 100 anterior renal tumors were included. Results 78% of tumors were T1a and 22% T1b with mean maximal tumoral dimension of 29 mm (range: 6–62 mm) and mean distance to nearest critical structure 9 mm (range: 0–40 mm). Mean follow-up was 20.9 months (range: 3–103). 28% of PCAs required hydrodissection. Technical success was achieved in 92% of patients; with six remaining patients undergoing successful repeat PCA (secondary technical success: 98%). The remaining two patients without primary technical success were either surveilled or had a benign pathology on resulted concomitant biopsy. Four patients (4%) had major AEs (hemorrhage requiring prolonged admission, transfusion, or embolization (n = 3), perinephric abscess requiring drainage (n = 1)) and 27% had minor AEs. Eight patients (8%) had recurrence with a one-year OS of 94% and CSS of 100%. All recurrences underwent repeat ablation without additional recurrence and 3/8 (38%) were T1b and 5/8 (63%) were T1a tumors. Conclusion PCA of anterior renal tumors can be performed safely with high rates of technical and oncologic success.
- 11 May 2023
- Published by Elsevier in Clinical Imaging
- Vol. 100, 30-35
Limited ability of the renal ablation-specific (MC)2 risk scoring system to predict major adverse events from percutaneous renal microwave ablation
- 11 May 2023
- Published by Elsevier in Clinical Imaging
- Vol. 100, 30-35
Limited ability of the renal ablation-specific (MC)2 risk scoring system to predict major adverse events from percutaneous renal microwave ablation